首页> 外文期刊>Nature reviews Drug discovery >Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.
【24h】

Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.

机译:修改IGF1活性:一种治疗内分泌失调,动脉粥样硬化和癌症的方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Insulin-like growth factor 1 (IGF1) is a polypeptide hormone that has a high degree of structural similarity to human proinsulin. Owing to its ubiquitous nature and its role in promoting cell growth, strategies to inhibit IGF1 actions are being pursued as potential adjunctive measures for treating diseases such as short stature, atherosclerosis and diabetes. In addition, most tumour cell types possess IGF1 receptors and conditions in the tumour microenvironment, such as hypoxia, can lead to enhanced responsiveness to IGF1. Therefore, inhibiting IGF1 action has been proposed as a specific mechanism for potentiating the effects of existing anticancer therapies or for directly inhibiting tumour cell growth.
机译:胰岛素样生长因子1(IGF1)是一种多肽激素,与人胰岛素原的结构高度相似。由于其无处不在的性质及其在促进细胞生长中的作用,抑制IGF1作用的策略正在作为治疗诸如身材矮小,动脉粥样硬化和糖尿病等疾病的辅助手段。此外,大多数肿瘤细胞类型都具有IGF1受体,并且肿瘤微环境中的状况(例如缺氧)会导致对IGF1的反应性增强。因此,已经提出抑制IGF1的作用是增强现有抗癌疗法效果或直接抑制肿瘤细胞生长的特定机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号